Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.

Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - The ATLAS trial.

Detalhes bibliográficos
Principais autores:	Van der Heijde, D, Luo, M, Matsumoto, A, Mease, P, Torre-Alonso, J, Wordsworth, P, Wong, R, Davis, J, Grp, A
Formato:	Conference item
Publicado em:	2005

Registros relacionados

Adalimumab enhances health-related quality of life in patients with active ankylosing spondylitis - Results from the atlas trial
por: van der Heijde, D, et al.
Publicado em: (2006)

Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) patients: Results from ATLAS.
por: van der Heijde, D, et al.
Publicado em: (2006)

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
por: Revicki, D, et al.
Publicado em: (2008)

Improved physical functioning and work productivity in ankylosing spondylitis (AS) patients who were treated with adalimumab-ATLAS trial results
por: Vanderheijde, D, et al.
Publicado em: (2007)

Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS.
por: van der Heijde, D, et al.
Publicado em: (2006)

Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS)
por: van der Heijde, D, et al.
Publicado em: (2008)

Improvements in health related quality of life (HRQL) correlate positively with clinical reponses in ankylosing spondylitis (AS) patients - Results from ATLAS
por: Van der Heijde, D, et al.
Publicado em: (2006)

Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas
por: Wordsworth, P, et al.
Publicado em: (2008)

Effect of adalimumab on quality of life in patients with active ankylosing spondylitis
por: Cao Shuangyan, Shao Zhanqin, Gu Jieruo
Publicado em: (2023-06-01)

Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis
por: Tatyana Valentinovna Mezenova, et al.
Publicado em: (2012-04-01)

Efficacy of adalimumab in uveitis in patients with ankylosing spondylitis
por: Shandor Fedorovich Erdes
Publicado em: (2012-03-01)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Sanjiv Kapoor, et al.
Publicado em: (2019-10-01)

EXPERIENCE OF ADALIMUMAB TREATMENT IN PATIENT WITH JUVENILE ANKYLOSING SPONDYLITIS AND UVEITIS
por: E. V. Mitenko, et al.
Publicado em: (2012-02-01)

Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab
por: M. Fernandes, et al.
Publicado em: (2011-11-01)

EXPERIENCE OF TREATMENT OF JUVENILE ANKYLOSING SPONDYLITIS WITH EYES LESION WITH ADALIMUMAB
por: E.I. Alexeeva, et al.
Publicado em: (2009-01-01)

EXPERIENCE OF TREATMENT OF JUVENILE ANKYLOSING SPONDYLITIS WITH EYES LESION WITH ADALIMUMAB
por: E.I. Alexeeva, et al.
Publicado em: (2009-01-01)

Adalimumab is effective and well-tolerated in patients with ankylosing spondylitis (AS) in day-to-day clinical practice - Results from rhapsody
por: Wordsworth, P, et al.
Publicado em: (2008)

Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
por: Junhong He, et al.
Publicado em: (2022-02-01)

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
por: Rudwaleit, M, et al.
Publicado em: (2009)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu Y, et al.
Publicado em: (2022-12-01)

Genetics of ankylosing spondylitis.
por: Brown, M, et al.
Publicado em: (2002)

LEUKOCYTOCLASTIC VASCULITIS ASSOCIATED WITH ADALIMUMAB TREATMENTIN A PATIENT WITH ANKYLOSING SPONDYLITIS
por: I A Doroshkevich, et al.
Publicado em: (2010-06-01)

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
por: Xiaoliang Ding, et al.
Publicado em: (2020-05-01)

Secretor status and ankylosing spondylitis.
por: Pal, A, et al.
Publicado em: (1998)

ANKYLOSING-SPONDYLITIS AND FUNCTIONAL ABILITY
por: Wordsworth, B, et al.
Publicado em: (1984)

Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with AS: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for AS (ATLAS) (vol 35, pg 1346, 2008)
por: Revicki, D, et al.
Publicado em: (2011)

IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS), ADALIMUMAB IMPROVES INFLAMMATORY BOWEL DISEASE (IBD) AND PSORIASIS (Ps) AND PREVENTS ANTERIOR UVEITIS (AU) FLARES
por: Wordsworth, P, et al.
Publicado em: (2009)

Allergic bronchopulmonary aspergillosis in a patient with ankylosing spondylitis treated with adalimumab
por: Yudai Suzuki, et al.
Publicado em: (2021-08-01)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Dubravka Bosnić, et al.
Publicado em: (2016-12-01)

THE ROLE OF ANKH IN ANKYLOSING SPONDYLITIS
por: Timms, A, et al.
Publicado em: (2003)

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
por: C McLeod, et al.
Publicado em: (2007-08-01)

ERAP1 and ankylosing spondylitis.
por: Keidel, S, et al.
Publicado em: (2013)

Genetic susceptibility to ankylosing spondylitis.
por: Sims, A, et al.
Publicado em: (2004)

Hypophosphataemia masquerading as ankylosing spondylitis
por: Wordsworth, B, et al.
Publicado em: (2008)

Susceptibility to ankylosing spondylitis.
por: Carter, N, et al.
Publicado em: (2000)

Clinical features of ankylosing spondylitis in the UK
por: Farrar, C, et al.
Publicado em: (2008)

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China
por: Liudan Tu, et al.
Publicado em: (2020-11-01)

Adalimumab (HUMIRA (R)) improves inflammatory bowel disease (IBD) and psoriasis (Ps) and prevents anterior uveitis (AU) flares in patients with Ankylosing spondylitis (AS)
por: Rudwaleit, M, et al.
Publicado em: (2008)

THE FIRST EXPERIENCE IN USING ADALIMUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: CLINICAL AND MRICOMPARISONS OF THE RESULTS OF THERAPY
por: A G Bochkova, et al.
Publicado em: (2010-02-01)

CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL
por: Wordsworth, P, et al.
Publicado em: (2009)